Skip to main content
Erschienen in: Endocrine Pathology 4/2015

01.12.2015

Pathology of Struma Ovarii: A Report of 96 Cases

verfasst von: Shuanzeng Wei, Zubair W. Baloch, Virginia A. LiVolsi

Erschienen in: Endocrine Pathology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Thyroid tissue is a relatively frequent component of mature teratoma and can occur in 5–20 % of cases. Struma ovarii is defined as ovarian goiter which comprises either entirely or predominantly thyroid tissue (>50 %). This also includes cases of mature teratoma with less than 50 % thyroid tissue but harboring thyroid-associated malignancy. A total of 118 patients with mature teratoma containing thyroid tissue were identified at our institution (1989 to 2014). Ninety-six cases were diagnosed struma ovarii, including 10 cases of papillary thyroid carcinoma, 1 case of highly differentiated follicular carcinoma of ovarian origin (HDFCO), 5 cases of strumal carcinoid, and 80 cases of struma ovarii (53 cases of thyroid-only struma ovarii). Six cases had diffuse adenomatous hyperplasia, and seven cases had focal adenomatous hyperplasia. There was no recurrence on follow-up except one of the papillary thyroid carcinomas. Concurrent primary ovarian lesions included: serous cystadenoma—3, mucinous cystadenoma—4, Brenner tumor—3, thecoma—2, ovarian fibroma—1, and focal hilus cell hyperplasia—4 cases. In this series, papillary thyroid carcinoma and strumal carcinoid were the most common well-differentiated neoplasm/malignancies arising in struma ovarii; these demonstrate a minimal or no aggressive clinical behavior.
Literatur
2.
Zurück zum Zitat Kurman RJ, Ellenson LH, Ronnett BM (2012) Blaustein’s Pathology of the Female Genital Tract. Springer US Kurman RJ, Ellenson LH, Ronnett BM (2012) Blaustein’s Pathology of the Female Genital Tract. Springer US
3.
Zurück zum Zitat Devaney K, Snyder R, Norris HJ, Tavassoli FA (1993) Proliferative and histologically malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol Pathol 12 (4):333–343CrossRefPubMed Devaney K, Snyder R, Norris HJ, Tavassoli FA (1993) Proliferative and histologically malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol Pathol 12 (4):333–343CrossRefPubMed
5.
Zurück zum Zitat Roth LM, Karseladze AI (2008) Highly differentiated follicular carcinoma arising from struma ovarii: a report of 3 cases, a review of the literature, and a reassessment of so-called peritoneal strumosis. Int J Gynecol Pathol 27 (2):213–222. doi:10.1097/PGP.0b013e318158e958 PubMed Roth LM, Karseladze AI (2008) Highly differentiated follicular carcinoma arising from struma ovarii: a report of 3 cases, a review of the literature, and a reassessment of so-called peritoneal strumosis. Int J Gynecol Pathol 27 (2):213–222. doi:10.​1097/​PGP.​0b013e318158e958​ PubMed
6.
Zurück zum Zitat Robboy SJ, Scully RE (1980) Strumal carcinoid of the ovary: an analysis of 50 cases of a distinctive tumor composed of thyroid tissue and carcinoid. Cancer 46 (9):2019–2034CrossRefPubMed Robboy SJ, Scully RE (1980) Strumal carcinoid of the ovary: an analysis of 50 cases of a distinctive tumor composed of thyroid tissue and carcinoid. Cancer 46 (9):2019–2034CrossRefPubMed
9.
Zurück zum Zitat Szyfelbein WM, Young RH, Scully RE (1994) Cystic struma ovarii: a frequently unrecognized tumor. A report of 20 cases. Am J Surg Pathol 18 (8):785–788CrossRefPubMed Szyfelbein WM, Young RH, Scully RE (1994) Cystic struma ovarii: a frequently unrecognized tumor. A report of 20 cases. Am J Surg Pathol 18 (8):785–788CrossRefPubMed
12.
Zurück zum Zitat Rashad MN, Fathalla MF, Kerr MG (1966) Sex chromatin and chromosome analysis in ovarian teratomas. Am J Obstet Gynecol 96 (4):461–465PubMed Rashad MN, Fathalla MF, Kerr MG (1966) Sex chromatin and chromosome analysis in ovarian teratomas. Am J Obstet Gynecol 96 (4):461–465PubMed
13.
Zurück zum Zitat Garg K, Soslow RA, Rivera M, Tuttle MR, Ghossein RA (2009) Histologically bland “extremely well differentiated” thyroid carcinomas arising in struma ovarii can recur and metastasize. Int J Gynecol Pathol 28 (3):222–230. doi:10.1097/PGP.0b013e31818a2b99 CrossRefPubMed Garg K, Soslow RA, Rivera M, Tuttle MR, Ghossein RA (2009) Histologically bland “extremely well differentiated” thyroid carcinomas arising in struma ovarii can recur and metastasize. Int J Gynecol Pathol 28 (3):222–230. doi:10.​1097/​PGP.​0b013e31818a2b99​ CrossRefPubMed
14.
Zurück zum Zitat Robboy SJ, Shaco-Levy R, Peng RY, Snyder MJ, Donahue J, Bentley RC, Bean S, Krigman HR, Roth LM, Young RH (2009) Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread. Int J Gynecol Pathol 28 (5):405–422. doi:10.1097/PGP.0b013e3181a27777 CrossRefPubMed Robboy SJ, Shaco-Levy R, Peng RY, Snyder MJ, Donahue J, Bentley RC, Bean S, Krigman HR, Roth LM, Young RH (2009) Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread. Int J Gynecol Pathol 28 (5):405–422. doi:10.​1097/​PGP.​0b013e3181a27777​ CrossRefPubMed
15.
Zurück zum Zitat Shaco-Levy R, Peng RY, Snyder MJ, Osmond GW, Veras E, Bean SM, Bentley RC, Robboy SJ (2012) Malignant struma ovarii: a blinded study of 86 cases assessing which histologic features correlate with aggressive clinical behavior. Arch Pathol Lab Med 136 (2):172–178. doi:10.5858/arpa.2011-0092-OA CrossRefPubMed Shaco-Levy R, Peng RY, Snyder MJ, Osmond GW, Veras E, Bean SM, Bentley RC, Robboy SJ (2012) Malignant struma ovarii: a blinded study of 86 cases assessing which histologic features correlate with aggressive clinical behavior. Arch Pathol Lab Med 136 (2):172–178. doi:10.​5858/​arpa.​2011-0092-OA CrossRefPubMed
17.
Zurück zum Zitat Yip L, Nikiforova MN, Yoo JY, McCoy KL, Stang MT, Armstrong MJ, Nicholson KJ, Ohori NP, Coyne C, Hodak SP, Ferris RL, LeBeau SO, Nikiforov YE, Carty SE (2015) Tumor Genotype Determines Phenotype and Disease-related Outcomes in Thyroid Cancer: A Study of 1510 Patients. Ann Surg 262 (3):519–525. doi:10.1097/sla.0000000000001420 CrossRefPubMed Yip L, Nikiforova MN, Yoo JY, McCoy KL, Stang MT, Armstrong MJ, Nicholson KJ, Ohori NP, Coyne C, Hodak SP, Ferris RL, LeBeau SO, Nikiforov YE, Carty SE (2015) Tumor Genotype Determines Phenotype and Disease-related Outcomes in Thyroid Cancer: A Study of 1510 Patients. Ann Surg 262 (3):519–525. doi:10.​1097/​sla.​0000000000001420​ CrossRefPubMed
18.
Zurück zum Zitat Howitt BE, Paulson VA, Barletta JA (2015) Absence of BRAF V600E in non-infiltrative, non-invasive follicular variant of papillary thyroid carcinoma. Histopathology. doi:10.1111/his.12680 PubMed Howitt BE, Paulson VA, Barletta JA (2015) Absence of BRAF V600E in non-infiltrative, non-invasive follicular variant of papillary thyroid carcinoma. Histopathology. doi:10.​1111/​his.​12680 PubMed
19.
Zurück zum Zitat Miettinen M, Karkkainen P (1996) Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Virchows Arch 429 (4–5):213–219PubMed Miettinen M, Karkkainen P (1996) Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Virchows Arch 429 (4–5):213–219PubMed
20.
Zurück zum Zitat Barroeta JE, Baloch Z, Lal P, Pasha TL, Zhang PJ, LiVolsi V (2006) Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocrine pathology 17 (3):225–234CrossRefPubMed Barroeta JE, Baloch Z, Lal P, Pasha TL, Zhang PJ, LiVolsi V (2006) Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocrine pathology 17 (3):225–234CrossRefPubMed
21.
Zurück zum Zitat Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, Chapelle Adl, Kloos RT (2004) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18 (1):48–57CrossRef Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, Chapelle Adl, Kloos RT (2004) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18 (1):48–57CrossRef
22.
Zurück zum Zitat Rouzbahman M, Clarke B Neuroendocrine tumors of the gynecologic tract: select topics. In: Seminars in diagnostic pathology, 2013. vol 3. Elsevier, pp 224–233 Rouzbahman M, Clarke B Neuroendocrine tumors of the gynecologic tract: select topics. In: Seminars in diagnostic pathology, 2013. vol 3. Elsevier, pp 224–233
28.
Zurück zum Zitat Terada T, Tateoka K (2012) Ovarian cystic tumor composed of Brenner tumor and struma ovarii. Int J Clin Exp Pathol 5 (3):274–277PubMedCentralPubMed Terada T, Tateoka K (2012) Ovarian cystic tumor composed of Brenner tumor and struma ovarii. Int J Clin Exp Pathol 5 (3):274–277PubMedCentralPubMed
Metadaten
Titel
Pathology of Struma Ovarii: A Report of 96 Cases
verfasst von
Shuanzeng Wei
Zubair W. Baloch
Virginia A. LiVolsi
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 4/2015
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-015-9396-1

Weitere Artikel der Ausgabe 4/2015

Endocrine Pathology 4/2015 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …